Atrys Health (ATRY.MC) Stock Price

Atrys Health Price

BME·CLOSED
2.47EUR-0.02 (-1.01 %)
Market closed

Revenue has compounded at 61.4% per year over the past 9 years to 212.74 M EUR. Earnings per share have declined at 85.0% per year over the last 3 years. Atrys Health's net margin stands at -14.9%, down from -6.4% several years earlier. Analysts set a median price target of 5.76 EUR, implying 133.3% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 6% above its 52-week low.

Atrys Health stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Atrys Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Atrys Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Atrys Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Atrys Health Stock Price History
DateAtrys Health Price
7/23/20262.47 EUR
7/22/20262.49 EUR
7/21/20262.44 EUR
7/20/20262.43 EUR
7/17/20262.38 EUR
7/16/20262.41 EUR
7/15/20262.34 EUR
7/14/20262.40 EUR
7/13/20262.49 EUR
7/10/20262.47 EUR
7/9/20262.49 EUR
7/8/20262.53 EUR
7/7/20262.60 EUR
7/6/20262.58 EUR
7/3/20262.55 EUR
7/2/20262.52 EUR
7/1/20262.53 EUR
6/30/20262.54 EUR
6/29/20262.55 EUR
6/26/20262.58 EUR
6/25/20262.58 EUR
6/24/20262.57 EUR
6/23/20262.59 EUR
6/22/20262.58 EUR
6/19/20262.64 EUR
6/18/20262.71 EUR
6/17/20262.69 EUR
6/16/20262.63 EUR
6/15/20262.68 EUR
6/12/20262.66 EUR
6/11/20262.67 EUR
6/10/20262.65 EUR
6/9/20262.66 EUR
6/8/20262.70 EUR
6/5/20262.77 EUR
6/4/20262.81 EUR
6/3/20262.79 EUR
6/2/20262.75 EUR
6/1/20262.72 EUR
5/29/20262.82 EUR
5/28/20262.79 EUR
5/27/20262.78 EUR
5/26/20262.78 EUR
5/25/20262.76 EUR
5/22/20262.81 EUR
5/21/20262.81 EUR
5/20/20262.72 EUR
5/19/20262.67 EUR
5/18/20262.67 EUR
5/15/20262.69 EUR
5/14/20262.73 EUR
5/13/20262.71 EUR
5/12/20262.70 EUR
5/11/20262.72 EUR
5/8/20262.73 EUR
5/7/20262.74 EUR
5/6/20262.81 EUR
5/5/20262.85 EUR
5/4/20262.76 EUR
4/30/20262.82 EUR
4/29/20262.82 EUR
4/28/20262.86 EUR
4/27/20262.92 EUR
4/24/20262.90 EUR
4/23/20262.89 EUR
4/22/20262.90 EUR
4/21/20262.93 EUR
4/20/20262.95 EUR
4/17/20263.01 EUR
4/16/20263.04 EUR
4/15/20262.99 EUR
4/14/20262.98 EUR
4/13/20262.95 EUR
4/10/20262.87 EUR
4/9/20262.74 EUR
4/8/20262.81 EUR
4/7/20262.94 EUR
4/2/20262.87 EUR
3/27/20262.76 EUR
3/26/20262.83 EUR
3/25/20262.76 EUR
3/24/20262.74 EUR
3/23/20262.70 EUR
3/20/20262.78 EUR
3/19/20262.80 EUR
3/17/20262.88 EUR
3/16/20262.94 EUR
3/13/20262.81 EUR
3/12/20262.87 EUR
3/11/20262.83 EUR
3/10/20262.80 EUR
3/9/20262.72 EUR
3/6/20262.81 EUR
3/5/20262.83 EUR
2/27/20262.95 EUR
2/26/20262.96 EUR
2/25/20263.02 EUR
2/24/20263.03 EUR
2/23/20263.09 EUR
2/20/20263.08 EUR
2/19/20263.10 EUR
2/18/20263.09 EUR
2/17/20263.07 EUR
2/16/20263.08 EUR
2/13/20263.05 EUR
2/12/20262.91 EUR
2/11/20262.90 EUR
2/10/20262.93 EUR
2/9/20262.93 EUR
2/6/20262.93 EUR
2/5/20262.93 EUR
2/4/20262.94 EUR
2/3/20262.97 EUR
2/2/20262.94 EUR
1/30/20262.94 EUR
1/29/20263.00 EUR
1/28/20263.02 EUR
1/27/20263.00 EUR
1/26/20263.03 EUR
1/23/20263.06 EUR
1/22/20262.96 EUR
1/21/20262.91 EUR
1/20/20262.99 EUR
1/19/20263.07 EUR
1/16/20262.98 EUR
1/15/20263.04 EUR
1/14/20263.05 EUR
1/13/20263.05 EUR
1/12/20263.13 EUR
1/9/20263.13 EUR
1/8/20263.05 EUR
1/7/20262.98 EUR
1/6/20262.96 EUR
1/5/20262.92 EUR
1/2/20262.90 EUR
12/31/20252.93 EUR
12/30/20252.79 EUR
12/29/20252.78 EUR
12/24/20252.73 EUR
12/23/20252.84 EUR
12/22/20252.77 EUR
12/19/20252.77 EUR
12/18/20252.74 EUR
12/17/20252.63 EUR
12/16/20252.68 EUR
12/15/20252.74 EUR
12/12/20252.77 EUR
12/11/20252.70 EUR
12/10/20252.73 EUR
12/9/20252.72 EUR
12/8/20252.72 EUR
12/5/20252.70 EUR
12/4/20252.68 EUR
12/3/20252.70 EUR
12/2/20252.70 EUR
12/1/20252.70 EUR
11/28/20252.78 EUR
11/27/20252.69 EUR
11/26/20252.67 EUR
11/25/20252.69 EUR
11/24/20252.68 EUR
11/21/20252.64 EUR
11/20/20252.67 EUR
11/19/20252.70 EUR
11/18/20252.67 EUR
11/17/20252.75 EUR
11/14/20252.86 EUR
11/13/20252.90 EUR
11/12/20252.89 EUR
11/11/20252.87 EUR
11/10/20252.93 EUR
11/7/20252.99 EUR
11/6/20253.11 EUR
11/5/20253.15 EUR
11/4/20253.18 EUR
11/3/20253.19 EUR
10/31/20253.16 EUR
10/30/20253.20 EUR
10/29/20253.22 EUR
10/28/20253.38 EUR
10/27/20253.37 EUR
10/24/20253.52 EUR
10/23/20253.48 EUR
10/22/20253.51 EUR
10/21/20253.43 EUR
10/20/20253.47 EUR
10/17/20253.24 EUR
10/16/20253.30 EUR
10/15/20253.30 EUR
10/14/20253.27 EUR
10/13/20253.48 EUR
10/10/20253.39 EUR
10/9/20253.46 EUR
10/8/20253.47 EUR
10/7/20253.30 EUR
10/6/20252.89 EUR
10/3/20252.79 EUR
10/2/20252.75 EUR
10/1/20252.74 EUR
9/30/20252.76 EUR
9/29/20252.80 EUR
9/26/20252.78 EUR
9/25/20252.77 EUR
9/24/20252.72 EUR
9/23/20252.75 EUR
9/22/20252.81 EUR
9/19/20252.76 EUR
9/18/20252.77 EUR
9/17/20252.76 EUR
9/16/20252.80 EUR
9/15/20252.78 EUR
9/12/20252.82 EUR
9/11/20252.82 EUR
9/10/20252.83 EUR
9/9/20252.79 EUR
9/8/20252.83 EUR
9/5/20252.84 EUR
9/4/20252.84 EUR
9/3/20252.86 EUR
9/2/20252.84 EUR
9/1/20252.83 EUR
8/29/20252.87 EUR
8/28/20252.80 EUR
8/27/20252.90 EUR
8/26/20252.82 EUR
8/25/20252.84 EUR
8/22/20252.88 EUR
8/21/20252.87 EUR
8/20/20252.88 EUR
8/19/20252.93 EUR
8/18/20252.92 EUR
8/15/20252.90 EUR
8/14/20252.89 EUR
8/13/20252.89 EUR
8/12/20252.86 EUR
8/11/20252.86 EUR
8/8/20252.82 EUR
8/7/20252.81 EUR
8/6/20252.82 EUR
8/5/20252.85 EUR
8/4/20252.88 EUR
8/1/20252.86 EUR
7/31/20252.92 EUR
7/30/20252.86 EUR
7/29/20252.91 EUR
7/28/20252.96 EUR
7/25/20253.04 EUR
7/24/20253.00 EUR
Access this data via the Eulerpool API
Get Free API Key

Atrys Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
121.01 M EUR
-15.01 M EUR
-23.26 M EUR
Jan 1, 2022
158.37 M EUR
-10.46 M EUR
-23.15 M EUR
Jan 1, 2023
201.57 M EUR
-1.16 M EUR
-45.59 M EUR
Jan 1, 2024
212.74 M EUR
7.72 M EUR
-31.77 M EUR
Jan 1, 2025 (e)
232.97 M EUR
17.14 M EUR
-12.55 M EUR
Jan 1, 2026 (e)
194.82 M EUR
16.93 M EUR
5.89 M EUR
Jan 1, 2027 (e)
208.28 M EUR
23.05 M EUR
9.76 M EUR
Jan 1, 2028 (e)
183.40 M EUR
19.84 M EUR
12.41 M EUR

Atrys Health Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 23, 2026, 7:36 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e
2.004.006.007.0014.0031.00121.00158.00201.00212.00232.00194.00208.00183.00
–100.0050.0016.67100.00121.43290.3230.5827.225.479.43-16.387.22-12.02
150.00100.0083.3385.7185.7177.4282.6479.7570.1568.4068.4068.4068.4068.40
3.004.005.006.0012.0024.00100.00126.00141.00145.00158.68132.69142.26125.17
––––1.001.00-15.00-10.00-1.007.0017.0016.0023.0019.00
––––7.143.23-12.40-6.33-0.503.307.338.2511.0610.38
1.00––––-2.00-23.00-23.00-45.00-31.00-12.005.009.0012.00
––––––1,050.00–95.65-31.11-61.29-141.6780.0033.33
7.1311.8010.9619.6321.4628.3250.2868.2075.8175.9375.9375.9375.9375.93
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Atrys Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Atrys Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Atrys Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Atrys Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Atrys Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Atrys Health stock margins

The Atrys Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Atrys Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Atrys Health.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
77.24 %
6.11 %
-6.42 %
Jan 1, 2021
83.37 %
-12.40 %
-19.22 %
Jan 1, 2022
79.56 %
-6.60 %
-14.62 %
Jan 1, 2023
70.33 %
-0.58 %
-22.62 %
Jan 1, 2024
68.34 %
3.63 %
-14.94 %
Jan 1, 2025 (e)
68.34 %
7.36 %
-5.39 %
Jan 1, 2026 (e)
68.34 %
8.69 %
3.02 %
Jan 1, 2027 (e)
68.34 %
11.07 %
4.69 %

Atrys Health Stock Revenue, EBIT, Earnings per Share

The Atrys Health earnings per share therefore indicates how much revenue Atrys Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
1.11 EUR
0.07 EUR
-0.07 EUR
Jan 1, 2021
2.41 EUR
-0.30 EUR
-0.46 EUR
Jan 1, 2022
2.32 EUR
-0.15 EUR
-0.34 EUR
Jan 1, 2023
2.66 EUR
-0.02 EUR
-0.60 EUR
Jan 1, 2024
2.80 EUR
0.10 EUR
-0.42 EUR
Jan 1, 2025 (e)
3.07 EUR
0.23 EUR
-0.17 EUR
Jan 1, 2026 (e)
2.57 EUR
0.22 EUR
0.08 EUR
Jan 1, 2027 (e)
2.74 EUR
0.30 EUR
0.13 EUR

Atrys Health business model & stock analysis

Atrys Health SA is a leading provider of medical services, founded in 2007 in Madrid, Spain, as a spin-off company of the Clinica Universidad de Navarra. The company's goal is to connect the limitless world of science and technology with the human component of healthcare. The business model of Atrys Health specializes in the development of products, services, and solutions in the field of medical imaging and cancer treatment. The company offers innovative technologies and medical services to help diagnose and treat patients better. Atrys Health consists of different business divisions focusing on the needs of clinical practice, research and development, and biotechnological production. The company aims to improve the efficiency and effectiveness of diagnosis, imaging, and treatment technologies to maximize results. The divisions of Atrys Health focus on various aspects of healthcare, including telemedicine, radiology, and proton therapy. Telemedicine provides a platform for remote treatments and medical consultation, improving access to specialists and enabling fast and effective diagnosis and treatment. The radiology division operates diagnostic centers specializing in medical imaging, equipped with the latest imaging technologies. The proton therapy division operates a proton therapy center in Madrid, offering advanced cancer treatment. Atrys Health offers a range of products tailored to the needs of clinical practice, research and development, and biotechnological production. Their key products include Atrilab, a leading platform for precision oncology diagnostics, Auriculum, a technology for precise radiation in cancer treatments, and Vida Oncology, a software solution for cancer treatment management. In conclusion, Atrys Health is a key player in medical imaging and cancer treatment, improving healthcare globally with advanced technologies and services. With their vision of combining innovative technologies with the human component of healthcare, Atrys Health will continue to lead in the healthcare industry.

Atrys Health SWOT Analysis

Strengths

Atrys Health SA has several strengths that contribute to its success in the healthcare industry. Firstly, the company has a strong reputation for providing high-quality medical services and solutions to its customers. This reputation has been built over time through the company's commitment to excellence and continuous improvement.

Secondly, Atrys Health SA has a well-established network of healthcare professionals and facilities, allowing them to deliver effective and efficient healthcare services to a wide range of patients. This network provides the company with a competitive advantage and enables them to serve a larger customer base.

Additionally, Atrys Health SA has a strong financial position, which allows them to invest in advanced technologies and research and development. This financial stability enables the company to stay ahead of industry trends and provide innovative solutions to its customers.

Weaknesses

Despite its strengths, Atrys Health SA also faces a few weaknesses that need to be addressed. One weakness is the high dependency on a few key healthcare professionals within the company. This dependence creates a potential risk as the loss or unavailability of these professionals may impact the company's ability to deliver services effectively.

Another weakness is the limited geographical presence of Atrys Health SA. While the company has a strong presence in certain regions, expanding into new markets and geographies could be challenging and require significant investment.

Opportunities

Atrys Health SA has several opportunities that it can leverage to further grow and expand its business. One opportunity is the increasing demand for advanced medical technologies and solutions. By investing in research and development, the company can develop innovative products and services that cater to this growing market demand.

Another opportunity lies in strategic partnerships and collaborations with other healthcare organizations. By forming alliances, Atrys Health SA can access new markets, share resources, and expand its customer base, leading to increased revenue and market share.

Threats

In the highly competitive healthcare industry, Atrys Health SA faces several threats that it needs to be mindful of. One major threat is the emergence of new competitors in the market. These competitors may offer similar products and services, potentially eroding Atrys Health SA's market share.

Furthermore, regulatory changes and compliance requirements pose a threat to the company. Adapting to new regulations and ensuring compliance can be both time-consuming and expensive.

Lastly, economic downturns and uncertainties in the global economy can impact the demand for healthcare services, potentially affecting Atrys Health SA's revenue and profitability.

Atrys Health Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Atrys Health historical P/E ratio, EBIT multiple, and P/S ratio

Atrys Health annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Atrys Health shares outstanding

The number of shares of Atrys Health was 75.93 M in 2025. This indicates how many shares Atrys Health is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
28.32 M Stocks
Jan 1, 2021
50.28 M Stocks
Jan 1, 2022
68.20 M Stocks
Jan 1, 2023
75.81 M Stocks
Jan 1, 2024
75.93 M Stocks
Jan 1, 2025 (e)
75.93 M Stocks
Jan 1, 2026 (e)
75.93 M Stocks
Jan 1, 2027 (e)
75.93 M Stocks

Current Atrys Health forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy90.00 % (9)
Hold10.00 % (1)
Sell0.00 % (0)
12M Price Target
5.76
Last Price
2.47
Currency
EUR
12M Return Potential
133.32 %
LTM Return
0 %

Atrys Health shareholder structure

% Name
24.84759%
Elias Navarro (Francisco Jose)
Elias Navarro (Francisco Jose)
6.52725%
Ybarra Careaga (Carmen)
Ybarra Careaga (Carmen)
6.39710%
Global Portfolio Investments SL
Global Portfolio Investments SL
5.43604%
Riberas Mera (Juan Maria)
Riberas Mera (Juan Maria)
5.13570%
Echarri Torres (Josep Maria)
Echarri Torres (Josep Maria)
3.12347%
Jose Maria (Galindez Zubiria)
Jose Maria (Galindez Zubiria)

Atrys Health Executives and Management Board

SS

Mr. Santiago De Torres Sanahuja

Chairman of the Board, Other External Director

Compensation210,000.00 EUR
IF

Ms. Isabel Lozano Fernandez

Other External Director

Compensation199,000.00 EUR
JF

Mr. Jaime Cano Fernandez

External Independent Director

Compensation55,000.00 EUR
AP

Ms. Ana Isabel Lopez Porta

External Proprietary Director

Compensation40,000.00 EUR
MD

Ms. Miryan Mercedes Gonzalez Durantez

External Independent Director

Compensation34,000.00 EUR

Atrys Health Supply Chain

Atrys Health Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
Varian Medical Systems, Inc.
Supplier
-0.87
-0.26
-0.86
—
—

Frequently asked questions about Atrys Health

The business model of Atrys Health SA revolves around providing advanced medical services and solutions. Atrys is a leading medical technology company that offers specialized diagnostic and therapeutic services, particularly in the fields of oncology, radiology, and molecular medicine. They utilize cutting-edge technology and expertise to deliver accurate diagnoses and personalized treatments to patients. Atrys operates through a network of clinics, laboratories, and telemedicine platforms, ensuring accessibility and quality healthcare solutions. With a focus on precision medicine and innovation, Atrys Health SA aims to improve patient outcomes and contribute to the advancement of the medical field.

All fundamentals and in-depth analysis of Atrys Health

Our stock analysis for Atrys Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atrys Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Atrys Health Stock
Atrys Health Revenue→
Atrys Health Stock
Atrys Health Net Income→
Atrys Health Stock
Atrys Health P/E→
Atrys Health Stock
Atrys Health P/S→
Atrys Health Stock
Atrys Health EBIT→
Atrys Health Stock
Atrys Health Dividend→
Atrys Health Stock
Atrys Health Directors Dealings→
Atrys Health Stock
Atrys Health Stocks→
Atrys Health Stock
Atrys Health Market capitalization→
Atrys Health Stock
Atrys Health Debt→
Atrys Health Stock
Atrys Health Liabilities→
Atrys Health Stock
Atrys Health Equity→
Atrys Health Stock
Atrys Health AAQS→
Atrys Health Stock
Atrys Health Employees→
Atrys Health Stock
Atrys Health ROE→
Atrys Health Stock
Atrys Health ROA→
Atrys Health Stock
Atrys Health ROCE→
Atrys Health Stock
Atrys Health News→
Atrys Health Stock
Atrys Health Analyst Price Targets→

Health Stocks

Attendo AB (publ)AtriCureaTyr PharmaAtossa TherapeuticsAunaAtonAura BiosciencesAtomo DiagnosticsAurinia PharmaceuticalsAtlas EnergyAurisco Pharmaceutical CoAtlantic InternationalAll Stocks A–Z →